| scholarly article | Q13442814 |
| P2093 | author name string | Terry K Bertin | |
| Brendan Lee | |||
| Irene Zolotukhin | |||
| Roland W Herzog | |||
| Masataka Suzuki | |||
| Donna J Palmer | |||
| Philip Ng | |||
| Geoffrey L Rogers | |||
| Racel G Cela | |||
| P2860 | cites work | Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus | Q45036081 |
| Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus | Q45269052 | ||
| The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver | Q45396033 | ||
| Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. | Q45857353 | ||
| In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. | Q45864497 | ||
| Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. | Q45865772 | ||
| Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo | Q45867544 | ||
| Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors | Q45870948 | ||
| Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo | Q45872399 | ||
| A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo | Q45877084 | ||
| Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation | Q46423291 | ||
| Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo | Q64376599 | ||
| Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene | Q80674687 | ||
| RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway | Q24317317 | ||
| Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector | Q24555782 | ||
| Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors | Q24673796 | ||
| Coagulation factor X activates innate immunity to human species C adenovirus | Q27332110 | ||
| Interferon-inducible antiviral effectors | Q27486790 | ||
| Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function | Q29617462 | ||
| The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response | Q29620414 | ||
| Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. | Q33337331 | ||
| A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency | Q33340517 | ||
| Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model | Q33371228 | ||
| Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors | Q33371239 | ||
| Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories | Q33691820 | ||
| Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates | Q33713289 | ||
| ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression | Q33713413 | ||
| MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus. | Q33832157 | ||
| Role and fate of PML nuclear bodies in response to interferon and viral infections | Q34435571 | ||
| Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement | Q34597583 | ||
| RETRACTED: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy | Q34621544 | ||
| Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus | Q34975214 | ||
| The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver | Q35067592 | ||
| NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo. | Q35226121 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways | Q35785201 | ||
| PML and PML nuclear bodies: implications in antiviral defence | Q36753891 | ||
| The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice | Q37286686 | ||
| Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges | Q37866086 | ||
| Immune responses to AAV in clinical trials | Q37873955 | ||
| Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands | Q39791660 | ||
| Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin | Q40304976 | ||
| Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector | Q40619684 | ||
| Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo | Q40883683 | ||
| Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo | Q40957520 | ||
| Host cell detection of noncoding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of transgene expression | Q42002320 | ||
| Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo | Q42579980 | ||
| Role for centromeric heterochromatin and PML nuclear bodies in the cellular response to foreign DNA. | Q42804321 | ||
| Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. | Q44592739 | ||
| A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. | Q44662326 | ||
| Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus | Q44663072 | ||
| Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors | Q44688725 | ||
| P433 | issue | 4 | |
| P921 | main subject | Adenoviridae | Q193447 |
| P304 | page(s) | 796-805 | |
| P577 | publication date | 2013-01-15 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo | |
| P478 | volume | 21 |
| Q39017189 | A view of human haematopoietic development from the Petri dish |
| Q41925180 | Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer |
| Q38714964 | Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors |
| Q38345989 | Cartilage tissue engineering: recent advances and perspectives from gene regulation/therapy |
| Q36664224 | Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy |
| Q36543422 | Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease |
| Q45873942 | Current and Future Treatments for Lysosomal Storage Disorders |
| Q34794525 | Development of Gene Transfer for Induction of Antigen-specific Tolerance |
| Q26823376 | Developments in the treatment of hemophilia B: focus on emerging gene therapy |
| Q57803544 | Exposure to wild-type AAV drives distinct capsid immunity profiles in humans |
| Q51847569 | Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. |
| Q91938979 | Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity |
| Q28081911 | Gene therapy for hemophilia |
| Q33881920 | Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. |
| Q38694359 | Global Screening of Antiviral Genes that Suppress Baculovirus Transgene Expression in Mammalian Cells |
| Q36976498 | IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression |
| Q92851595 | Immune Responses to Viral Gene Therapy Vectors |
| Q36983740 | Immune responses to AAV vectors: overcoming barriers to successful gene therapy |
| Q92345026 | Immunology of Adenoviral Vectors in Cancer Therapy |
| Q27016090 | Induced pluripotent stem cells in hematology: current and future applications |
| Q40045829 | In Vivo Hematopoietic Stem Cell Transduction. |
| Q36293848 | Multiple sclerosis: getting personal with induced pluripotent stem cells |
| Q90127107 | Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors |
| Q41922823 | One microRNA controls both angiogenesis and TLR-mediated innate immunity to nucleic acids |
| Q38977109 | Progress towards generation of human haematopoietic stem cells |
| Q38886593 | Recent advances in oncolytic adenovirus therapies for cancer |
| Q21245486 | Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B |
| Q90349121 | Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research |
| Q26751281 | The interplay of post-translational modification and gene therapy |
| Q35561776 | Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer |
Search more.